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anBACKGROUND Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular
events.
OBJECTIVES This study evaluated the association between high-sensitivity cardiac troponin I concentration and car-
diovascular events in patients with COPD and heightened cardiovascular risk.
METHODS In a double-blind randomized controlled trial, 16,485 patients with COPD and cardiovascular disease or
risk factors were randomized to once daily inhaled placebo, ﬂuticasone furoate (100 mg), vilanterol (25 mg), or their
combination. Plasma high-sensitivity cardiac troponin I concentrations were measured in a subgroup of 1,599 patients.
Outcomes were on-treatment cardiovascular events and COPD exacerbations over a median of 18 months, and
cardiovascular death over a median of 27 months.
RESULTS Baseline plasma cardiac troponin I concentrations were above the limit of detection (1.2 ng/l) in 1,542
(96%) patients. Concentrations were unaffected by inhaled therapies at 3 months (p > 0.05). Compared with the
lowest quintile (cardiac troponin <2.3 ng/l), patients in the highest quintile ($7.7 ng/l) were at greater risk of
cardiovascular events (hazard ratio [HR] 3.7; 95% conﬁdence interval [CI]: 1.3 to 10.1; p ¼ 0.012) and cardiovascular
death (HR: 20.1; 95% CI: 2.4 to 165.2; p ¼ 0.005) after adjustment for risk factors. By contrast, there were no differences
in exacerbations between quintiles (HR: 1.1; 95% CI: 0.8 to 1.5; p ¼ 0.548).
CONCLUSIONS In patients with COPD and heightened cardiovascular risk, plasma cardiac troponin I concentrations
are a speciﬁc and major indicator of future cardiovascular events and cardiovascular death. Inhaled therapies did
not affect cardiac troponin I concentrations consistent with their neutral effect on mortality and cardiovascular
outcomes. (Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic
Obstructive Pulmonary Disease [SUMMIT]; NCT01313676) (J Am Coll Cardiol 2018;72:1126–37) © 2018 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under
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AND ACRONYMS
CI = conﬁdence interval
COPD = chronic obstructive
pulmonary disease
CV = cardiovascular
FEV1, = forced expiratory
volume in 1 s
HR = hazard ratio
ICS = inhaled corticosteroid
IQR = interquartile range
LABA = long-acting beta-
agonistC ardiovascular (CV) disease, includingischemic heart disease and stroke, accountsfor 1 in 4 deaths globally and is increasing
in prevalence (1). Despite recent advances in under-
standing risk factors and therapeutic interventions,
atherosclerotic events remain unacceptably common.
Residual risk is particularly high among patients with
proinﬂammatory comorbidities, such as chronic
obstructive pulmonary disease (COPD) (2). In some
cases, it remains unclear whether it is the disease pro-
cess itself, or the off-target effects of the pharmaco-
logical treatments, that contribute to this elevated
risk (3).SEE PAGE 1138Notwithstanding prior major advances, future
clinical trial conduct is hampered by several impor-
tant and increasing challenges. It is well recognized
that clinical trial participants represent a relatively
low-risk subset of the real-world patient population.
Consequently, modest event rates necessitate large
and costly trials in order to demonstrate treatment
efﬁcacy. Conversely, this low event rate creates the
potential for researchers to fail to recognize CV harms
related to new medications before their clinical
approval (4). These challenges have contributed to
growing interest in the search for better biomarkers
suitable for use as a surrogate for treatment efﬁcacy
and safety. Such tests could provide an indication
of risk-beneﬁt balance in earlier-phase clinical trials
and may better inform the design of large-scale
clinical endpoint trials.
An ideal CV biomarker needs to be a sensitive as
well as a speciﬁc indicator of CV risk. High-sensitivity
cardiac troponin I is such a potential suitable
candidate. Plasma concentrations can be reliably
quantiﬁed in most apparently healthy individuals,
and numerous studies have demonstrated clear
associations between elevated plasma troponin
concentrations and CV events in both primary and
secondary prevention populations (5–11). Further-
more, plasma cardiac troponin I concentrations
measured by a high-sensitivity assay have recently
been shown to be modiﬁable, with statin-induced
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changes in serum cholesterol (12). The role of
serial testing with high-sensitivity cardiac
troponin I to predict the effect of other thera-
pies on CV outcomes has to date been unex-
plored in patients with more diverse
multimorbid conditions.
SUMMIT (Study to UnderstandMortality and
MorbidITy) (13,14) assessed the efﬁcacy and
safety of inhaled corticosteroids and long-
acting beta-agonists (LABAs) in 16,485 pa-
tients with COPD and heightened CV risk. This
was a multimorbid population with in-
terventions that could have both beneﬁt (15)
and harm (16). The present study reports post
hoc analyses aiming to determine whether plasma
high-sensitivity cardiac troponin I concentrations can
stratify CV risk, be modiﬁed by inhaled corticosteroids
(ICS) and bronchodilators, and predict outcomes
within the context of SUMMIT.
METHODS
STUDY POPULATION. The prospective, multicenter,
international randomized controlled SUMMIT trial
sought to determine whether treatment with an
inhaled LABA in combination with an ICS versus
either component, could improve clinical outcomes
in patients with moderate COPD and increased CV
risk compared with placebo. Details regarding
study design have been previously published (13,14).
In brief, eligible participants included current or
former smokers ($10 pack-years) between the ages
of 40 and 80 years, with a history of COPD and a
post-bronchodilator forced expiratory volume in 1 s
(FEV1) $50% and #70% of the predicted value,
a ratio of post-bronchodilator FEV1 to forced vital
capacity #0.70, and a score $2 on the modiﬁed
Medical Research Council dyspnea scale. Patients
were additionally required to have a history, or be at
increased risk, of CV disease. CV disease was deﬁned
as coronary artery disease, peripheral arterial
disease, prior stroke or myocardial infarction, or
diabetes mellitus with target organ disease.
Increased CV risk was deﬁned as being $60 yearsng medical education programs from the Canadian
iew, Pilot, Prime, Rare Disease Healthcare Commu-
vising and presenting from AstraZeneca, Boehringer
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1128and receiving medications for $2 of the following:
hypercholesterolemia, hypertension, diabetes melli-
tus, or peripheral vascular disease.
Although prior ICS and LABA treatments were
discontinued before study entry, other COPD medi-
cations were permitted during the trial. Participants
were then allocated equally to 1 of 4 randomized
treatments: placebo, ﬂuticasone furoate (100 mg),
vilanterol (25 mg), or their combination (ﬂuticasone
furoate/vilanterol, 100/25 mg) inhaled once daily as a
dry powder. A total of 16,485 patients were enrolled
and included in the ﬁnal intention-to-treat efﬁcacy
population.
ENDPOINTS. In addition to the primary endpoint of
all-cause mortality by intention-to-treat analysis,
the secondary CV endpoint was time to ﬁrst-on-
treatment CV event comprising CV death, myocar-
dial infarction, stroke, unstable angina, and transient
ischemic attack (17). Categorization of the cause of
each death was adjudicated by a clinical endpoint
committee blinded to the treatment allocation who
also determined whether any reported CV event
met the deﬁnition of the composite endpoint (13).
Individuals discontinuing study treatments could
not be assessed for the adjudicated composite CV
endpoint because follow-up visits were not per-
formed, and only data regarding mortality were
available. Another endpoint comprised moderate or
severe exacerbations of COPD. Moderate exacerba-
tions were deﬁned as a symptomatic deterioration
requiring treatment with antibiotic drugs or systemic
corticosteroids, whereas severe exacerbations were
deﬁned as events leading to hospital admission.
HIGH-SENSITIVITY CARDIAC TROPONIN I. Venous blood
samples were obtained before randomization and at
3 months. Blood was processed and plasma stored
at 80C until analyzed. As previously described,
before analysis, samples were thawed and underwent
centrifugation twice (3,000 relative centrifugal
force for 10 min) according to the manufacturer’s
instructions to ensure homogeneity (12). Plasma high-
sensitivity cardiac troponin I concentrations were
measured at a single site using the ARCHITECTSTAT
high-sensitive cardiac troponin I assay (Abbott Labo-
ratories, Abbott Park, Illinois), which has a limit of
detection of 1.2 ng/l, coefﬁcient of variation <10%
at 4.7 ng/l, and sex-speciﬁc 99th percentile upper
reference limits of 16 and 34 ng/l in women and men,
respectively (18,19).
STATISTICAL ANALYSIS. A value of 0.5 ng/l was
imputed for patients without reportable troponin
values. Cardiac troponin I concentrations were log-
transformed before statistical modeling, and resultstransformed back to the original scale. To determine
which patient characteristics were associated with
baseline cardiac troponin I, regression modeling was
performed. The ﬁnal model was achieved using
backwards selection where to remain in the model all
variables needed to have p < 0.10. To test whether ICS
or LABA therapy affected cardiac troponin I values at
3 months, an analysis of covariance was performed
adjusting for baseline cardiac troponin I, age, sex,
prior myocardial infarction and hypertension.
Patients were grouped into quintiles based on their
baseline cardiac troponin I concentrations. To explore
the effect of baseline cardiac troponin I quintile on
each of the study endpoints (CV composite, CV death,
and COPD exacerbations), analysis of time-to-ﬁrst
event was performed using Cox proportional haz-
ards regression modeling, adjusted for age, sex, study
therapy, and CV risk factors of prior myocardial
infarction and hypertension. In a sensitivity analysis,
we also included statin therapy and C-reactive pro-
tein concentrations as model covariates. Cardiac
troponin I was also examined as a continuous variable
where the best ﬁtting model was selected from a
variety of polynomial or logarithmic models using
2-term fractional polynomials (20).
Previous reports have identiﬁed that adverse
CV outcomes are associated with plasma troponin I
concentrations $5 ng/l (12,21). To explore this asso-
ciation further, and investigate whether the predic-
tive value of this threshold could be applied to
the SUMMIT population, patients were grouped
into those who had plasma concentrations <5 ng/l
at both baseline and 3 months, and those with a
concentration $5 ng/l at either baseline or 3 months.
Scientiﬁc oversight of the trial was provided by a
steering committee composed of academic experts
and employees from GlaxoSmithKline, who were
collectively responsible for the study design and
analysis, and for the review and interpretation of the
data. This study is registered with ClinicalTrials.gov
(NCT01313676).
RESULTS
The study population and principal ﬁndings of the
SUMMIT study have previously been described (14).
Between January 2011 and March 2014, 16,485 par-
ticipants were recruited and included in the primary
intention-to-treat analysis (17). Blood samples were
taken before randomization from 1,673 patients based
in the United States (SUMMIT biomarker population),
of which baseline cardiac troponin I concentrations
were assessed in 1,599 patients, and 1,258 had a sec-
ond troponin measurement performed 3 months after
TABLE 1 Patient Characteristics in the SUMMIT Study Population, the Biomarker Substudy Population, and Split by Cardiac Troponin I Quintile
Troponin Quintile 1
(<2.3 ng/l)
(n ¼ 307)
Troponin Quintile 2
($2.3 to <3.4 ng/l)
(n ¼ 32)
Troponin Quintile 3
($3.4 to <4.8 ng/l)
(n ¼ 31)
Troponin Quintile 4
($4.8 to <7.7 ng/l)
(n ¼ 33)
Troponin Quintile 5
($7.7 ng/l)
(n ¼ 31)
Biomarker
Substudy*
(n ¼ 1,67)
SUMMIT ITT-E
Population
(n ¼ 16,48)
Median troponin 1.7 2.8 4.0 5.8 12.0 4.0 -
Age, yrs 63  8 65  8 67  8 68  7 68  7 66  8 65  8
Female 172 (56) 153 (47) 107 (34) 98 (30) 80 (25) 635 (38) 4,196 (25)
BMI, kg/m2 30  6 31  7 31  6 31  7 31  7 31  7 28  6
Systolic blood pressure, mm Hg 128  14 129  16 132  16 131  16 134  19 131  16 135  15
Heart rate, beats/min 75  10 74  11 73  11 73  11 73  11 73  11 76  10
Estimated GFR, ml/min/1.73 m2 101.2  33.6 100.5  37.1 100.5  38.4 95.2  36.1 89.3  34.9 97.7  36.7 97.3  36.6
CRP, mg/l 5.3  6.9 6.5  8.3 5.6  7.0 6.5  10.3 6.8  8.7 6.2  8.3 6.2  8.3
Past medical history
Prior myocardial infarction or
coronary revascularization
71 (23) 89 (27) 112 (35) 145 (44) 162 (51) 601 (36) 3,436 (21)
Coronary artery disease 113 (37) 132 (41) 148 (46) 186 (56) 199 (63) 818 (49) 8,379 (51)
Congestive heart failure 15 (5) 11 (3) 21 (7) 34 (10) 61 (19) 146 (9) 3,456 (21)
Hypercholesterolemia 243 (79) 280 (86) 283 (89) 295 (89) 292 (92) 1458 (87) 11,518 (70)
Hypertension 258 (84) 285 (88) 300 (94) 307 (93) 302 (95) 1519 (91) 14,851 (90)
Diabetes mellitus 108 (35) 116 (36) 116 (36) 138 (42) 140 (44) 642 (38) 4,997 (30)
Family history of CVD 128 (42) 128 (39) 116 (36) 146 (44) 145 (46) 691 (41) 3,429 (21)
Respiratory history
Former smoker 141 (46) 152 (47) 170 (53) 178 (54) 169 (53) 845 (51) 8,807 (53)
Post-bronchodilator FEV1, l 1.7  0.4 1.7  0.4 1.7  0.4 1.7  0.4 1.7  0.4 1.7  0.4 1.7  0.4
Predicted post-
bronchodilator FEV1,
% of predicted
59.7  6.9 59.4  6.7 59.2  6.9 59.5  6.6 59.3  7.0 59.4  6.8 59.7  6.1
Exacerbations in 12 months
before study
0 220 (72) 233 (72) 228 (71) 249 (75) 236 (74) 1,215 (73) 10,021 (61)
1 55 (18) 57 (18) 58 (18) 47 (14) 55 (17) 290 (17) 4,020 (24)
2þ 32 (10) 35 (11) 33 (10) 34 (10) 27 (8) 168 (10) 2,444 (15)
Concomitant cardiovascular
therapy
Antiplatelet therapy 176 (57) 196 (60) 197 (62) 231 (70) 238 (75) 1,081 (65) 8,517 (52)
Statin therapy 207 (67) 251 (77) 238 (75) 269 (82) 245 (77) 1,263 (75) 10,721 (65)
Antiplatelet and statin
therapy
137 (45) 167 (51) 157 (49) 198 (60) 191 (60) 886 (53) 6151 (37)
Treatment allocation
Placebo 83 (27) 87 (27) 81 (25) 78 (24) 92 (29) 439 (26) 4,111 (25)
Fluticasone furoate 69 (22) 87 (27) 83 (26) 76 (23) 74 (23) 415 (25) 4,135 (25)
Vilanterol 87 (28) 84 (26) 70 (22) 80 (24) 77 (24) 416 (25) 4,118 (25)
Combination therapy 68 (22) 67 (21) 85 (27) 96 (29) 75 (24) 403 (24) 4,121 (25)
Values are mean  SD or n (%). *Of the 1,673 patients in the biomarker population, 74 did not have baseline cardiac troponin I measured and are therefore not included in the cardiac troponin I quintiles and
analyses.
BMI ¼ body mass index; CVD ¼ cardiovascular disease; FEV1 ¼ forced expiratory volume in 1 s; GFR ¼ glomerular ﬁltration rate; ITT-E ¼ intention-to-treat efﬁcacy.
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this analysis had established CV disease or diabetes
mellitus with end-organ damage (n ¼ 1,163 [73%]),
whereas a minority (n ¼ 407 [25%]) fulﬁlled the
criteria for an increased risk of CV disease only, and
29 (2%) did not meet the CV entry criteria.
DISTRIBUTION OF HIGH-SENSITIVITY CARDIAC TROPONIN
I CONCENTRATIONS AT BASELINE. Cardiac troponin I
concentrations were $1.2 ng/l in 1,542 participants
(96%) and above the sex-speciﬁc 99th percentile
(16 ng/l in women, 34 ng/l in men) in 42 participants(2.6%). The median cardiac troponin I concentration
was 4.0 ng/l (interquartile range [IQR]: 2.6 to 6.7 ng/l).
The patient characteristics in the biomarker
substudy population were broadly similar to the
overall SUMMIT population, except that those in
the biomarker population were more likely to be
female, have a higher body mass index, have fewer
previous COPD exacerbations, and have differences
in CV history and CV therapy (Table 1). Participants
were stratiﬁed into quintiles by plasma cardiac
troponin I concentration from samples obtained
before randomization. Compared with the lowest
TABLE 2 Patient Characteristics Associated With Baseline Cardiac Troponin I
Concentration
Univariate Models Multivariate Model
Cardiac
Troponin I Ratio p Value
Cardiac
Troponin I Ratio p Value*
Age, per 10-yr increase 1.266 <0.001 1.157 <0.001
Male vs. female 1.423 <0.001 1.461 <0.001
BMI, per 5 kg/m2 increase 1.043 0.007 1.102 <0.001
Heart rate, per 10 beats/min increase 0.962 0.039 — —
Systolic blood pressure, per 10 mm Hg
increase
1.059 <0.001 1.054 <0.001
Estimated GFR, per 10 ml/min increase 0.974 <0.001 0.965 <0.001
CRP, per 1 mg/l increase 1.005 0.041 — —
Past medical history vs. absence
Prior myocardial infarction or coronary
revascularization
1.407 <0.001 1.314 <0.001
Coronary artery disease 1.318 <0.001 — —
Congestive heart failure 1.714 <0.001 1.444 <0.001
Hypercholesterolemia 1.307 <0.001 — —
Hypertension 1.511 <0.001 1.330 <0.001
Diabetes mellitus 1.114 0.011 — —
Family history of CVD 1.062 0.158 — —
Respiratory history
Smoking status, former smoker vs
current smoker
1.098 0.025 0.908 0.019
Post-bronchodilator FEV1,
per liter increase
0.979 0.642 0.897 0.046
Exacerbations in 12 months before
study, vs. 0 exacerbations
1 0.920 0.135 — —
2þ 0.976 0.730 — —
Concomitant cardiovascular therapy vs.
absence
Antiplatelet therapy 1.223 <0.001 — —
Statin therapy 1.121 0.020 — —
Univariate models contain only that patient characteristic, unadjusted for any other characteristics. Multivariate
models also contain all other patient characteristics selected. Cardiac troponin I ratios are expressed relative to a
reference, for example, in the univariate model for age, for each 10-year increase, there was a 26.6% increase in
concentration; in the univariate model for sex, males had a 42.3% higher concentration than females. *p Value
after adjusting for all other covariates ﬁrst.
Abbreviations as in Table 1.
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($7.7 ng/l) were older, more likely to be male, former
smokers, have higher systolic blood pressure, a
history of ischemic heart disease, coronary artery
disease, congestive heart failure, hypercholester-
olemia, hypertension, diabetes mellitus, a family
history of myocardial infarction or stroke, and to be
receiving treatment with antiplatelet and statin
therapies.
A number of patient characteristics were associ-
ated with baseline plasma cardiac troponin I
concentration (Table 2). In a multivariate linear
regression model, higher baseline plasma cardiac
troponin I concentrations were associated with
increasing age, male sex, decreased renal function,
and other CV risk factors. After adjustment for othervariables, higher post-bronchodilator FEV1 was asso-
ciated with lower cardiac troponin I concentrations at
baseline.
BASELINE CARDIAC TROPONIN AND RISK OF
CLINICAL EVENTS. In the biomarker substudy,
during a median on-treatment follow-up of 1.5 (IQR:
0.8 to 2.5) years, there were 74 patients (4.6%) with a
composite CV event, and 587 (36.7%) patients with
moderate or severe exacerbations of COPD. During
a median on- and post-treatment follow-up of 2.3
(IQR: 1.6 to 3.1) years, there were 25 CV deaths.
Compared with the lowest quintile, participants
in the highest quintile were at greater risk of
experiencing a CV composite event (Figure 1A). This
difference persisted after adjustment for confounding
variables including CV risk factors (Table 3) (hazard
ratio [HR]: 3.67; 95% conﬁdence interval [CI]: 1.33
to 10.13; p ¼ 0.012). The association with increased CV
risk persisted in the sensitivity analysis with addi-
tional adjustment for C-reactive protein and statin
therapy (Online Table 1), and was also demonstrated
when troponin concentrations were considered in a
continuous manner (Central Illustration). Similarly,
there was a marked increased risk for CV death in the
highest quintile (Table 3) (HR: 20.06; 95% CI: 2.44
to 165.15; p ¼ 0.005) (Figure 1B). By contrast, there
was no difference between the highest and lowest
quintiles in the risk of moderate or severe COPD
exacerbations (Table 3) (HR: 1.09; 95% CI: 0.82 to 1.45;
p ¼ 0.548) (Figure 1C).
EFFECT OF TREATMENT ON CARDIAC TROPONIN AT
3 MONTHS. Plasma cardiac troponin I concentrations
at 3 months were unchanged from baseline (p > 0.05
for all treatments) (Table 4). There were no
treatment-related differences in the change in cardiac
troponin I concentration at 3 months (p > 0.05 for all
treatments). This was consistent with the lack
of treatment effect on the CV composite endpoint
(p > 0.05 for all active treatments vs. placebo) (Online
Table 2).
CARDIAC TROPONIN THRESHOLD AND CV EVENTS.
Of the 1,258 patients with baseline and 3-month
measurements, 673 (53%) had cardiac troponin
concentrations <5 ng/l on both occasions. Compared
with this group, patients who had a plasma
troponin $5 ng/l at either time point had increased
rates of the composite CV endpoint (HR: 2.02; 95% CI:
1.18 to 3.46) and a markedly increased risk of CV
death (HR: 6.76; 95% CI: 1.86 to 24.56) (Table 3,
Figure 2). By contrast, there was no difference in
the endpoint of COPD exacerbations (HR: 0.94;
95% CI: 0.78 to 1.13).
FIGURE 1 Baseline High-Sensitivity Cardiac Troponin and Risk of CV Composite Events, CV Death, and COPD Exacerbations
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Patients were grouped into quintiles based on their baseline cardiac troponin I concentrations. Compared with the lowest quintile (<2.3 ng/l), those in the highest
quintile ($7.7 ng/l) were at greater risk of experiencing a CV composite event (A) and CV death (B). By contrast, there was no difference between the highest and
lowest quintiles in the risk of moderate or severe COPD exacerbations (C). CI ¼ conﬁdence interval; COPD ¼ chronic obstructive pulmonary disease; CV ¼ cardiovascular.
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TABLE 3 Time to First CV Composite Event and Time to CV Death by Baseline Cardiac Troponin Quintiles and Cardiac Troponin I $5 ng/l
at Either Baseline or 3-Month Time Point
Troponin Quintile 1
(<2.3 ng/l)
(n ¼ 307)
Troponin Quintile 2
($2.3 to <3.4 ng/l)
(n ¼ 325)
Troponin Quintile 3
($3.4 to <4.8 ng/l)
(n ¼ 319)
Troponin Quintile 4
($4.8 to <7.7 ng/l)
(n ¼ 330)
Troponin Quintile 5
($7.7 ng/l)
(n ¼ 318)
Patients experiencing CV event* 5 (2) 9 (3) 16 (5) 23 (7) 21 (7)
Quintile vs. 1st quintile
Hazard ratio† 1.59 2.69 3.72 3.67
95% CI (0.53–4.75) (0.97–7.48) (1.37–10.09) (1.33–10.13)
p Value 0.409 0.059 0.010 0.012
CV death 1 (<1) 3 (<1) 3 (<1) 7 (2) 11 (3)
Quintile vs. 1st quintile
Hazard ratio† 3.02 3.72 10.34 20.06
95% CI (0.31–29.29) (0.38–36.91) (1.21–88.41) (2.44–165.15)
p Value 0.341 0.261 0.033 0.005
Patients experiencing a moderate or
severe COPD exacerbation
108 (35) 123 (38) 120 (38) 121 (37) 115 (36)
Quintile vs. 1st quintile
Hazard ratio‡ 1.08 1.01 1.02 1.09
95% CI (0.83–1.40) (0.77–1.33) (0.77–1.35) (0.82–1.45)
p Value 0.567 0.925 0.886 0.548
<5 ng/l at Both
Time Points
(n ¼ 673)
$5 ng/l at Either
Time Point
(n ¼ 585)
Patients experiencing CV event* 22 (3) 42 (7)
$5 ng/l vs. <5 ng/l
Hazard ratio† 2.02
95% CI (1.18–3.46)
p Value 0.011
CV death 3 (<1) 14 (2)
$5 ng/l vs <5 ng/l
Hazard ratio† 6.76
95% CI (1.86–24.56)
p Value 0.004
Patients experiencing a moderate or
severe COPD exacerbation
275 (41) 228 (39)
$5 ng/l vs. <5 ng/l
Hazard ratio‡ 0.94
95% CI (0.78–1.13)
p Value 0.491
Values are n (%) unless otherwise noted. *Composite CV event comprising any of: CV death, myocardial infarction, stroke, unstable angina, and transient ischemic attack.
†Cox proportional hazards model adjusted for inhaled treatment, age, sex, previous myocardial infarction, hypertension. ‡Cox proportional hazards model adjusted for inhaled
treatment, age, sex, previous myocardial infarction, hypertension, previous COPD exacerbation history.
CI ¼ conﬁdence interval; COPD ¼ chronic obstructive pulmonary disease; CV ¼ cardiovascular.
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We have identiﬁed a strong association between
plasma high-sensitivity cardiac troponin I concen-
tration and CV outcomes in patients with COPD at
heightened CV risk. Importantly, this relationship
was speciﬁc for CV events, particularly CV death, with
no demonstrable association with the risk of COPD
exacerbations despite the apparent association with
baseline pulmonary function. Possible mechanisms
underpinning this relationship have been described
previously and may include increased inﬂammation,
systemic hypoxia, or right ventricular strainassociated with pulmonary hypertension (22–27). In
addition, we have shown that the presence of change
in troponin concentration on repeat testing over a
3-month period also confers an increased risk of
CV events, perhaps reﬂecting underlying athero-
sclerotic instability. Furthermore, there was no
treatment-related change in plasma troponin con-
centrations, consistent with the overall neutral effect
on all-cause mortality and CV outcomes reported in
the primary trial analysis (14).
Our ﬁndings highlight the potential use of
high-sensitivity cardiac troponin concentration as a
surrogate biomarker endpoint in early-phase clinical
CENTRAL ILLUSTRATION High-Sensitivity Cardiac Troponin I Concentration Is a Strong,
Independent, and Speciﬁc Predictor of CV Death in Patients With COPD
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The association between baseline high-sensitivity cardiac troponin I and CV death (orange) and COPD exacerbations (blue) was examined
using cardiac troponin as a continuous variable. Hazard ratios are compared with the median troponin concentration in the ﬁrst quintile
(1.7 ng/l) and are adjusted for age, sex, previous myocardial infarction, hypertension, and exacerbation history. Shaded areas represent 95%
conﬁdence intervals. COPD ¼ chronic obstructive pulmonary disease; CV ¼ cardiovascular.
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important clinical implications. Recognizing the risk
associated with increased troponin concentrations
might encourage clinicians to address CV risk due to
lifestyle choices and make patients more likely
to engage with these recommendations. Similarly,
improved risk stratiﬁcation may facilitate more
appropriate targeting of preventive medications (12).
Patients with cardiac troponin concentrations in the
upper 2 quintiles are clearly at high risk of CV events,
and above the thresholds used in international
guidelines for the initiation of lifestyle modiﬁcation
and primary prevention therapies (28–30). Given that
only 60% of these individuals were receiving both
antiplatelet and statin therapy, there is a sizeable
residual “treatment gap.” By contrast, nearly one-halfof the lowest quintile were currently receiving this
combination from which they may be deriving limited
beneﬁt given their low-risk proﬁle.
This study has a number of notable strengths that
distinguish it from previous reports on the use of
plasma cardiac troponin within the outpatient setting.
First, trial participants comprised a broad spectrum of
risk, including primary and secondary prevention
populations. Second, as a substudy within the context
of a large international randomized trial, we ensured
comprehensive follow-up and rigorous adjudication
of clinical events. Third, the troponin assay chosen for
this analysis is both widely available and analytically
robust with <5% of samples below the limit of detec-
tion. Finally, the availability of paired plasma
samples pre-treatment and after 3 months of
TABLE 4 Effect of Inhaled Study Treatment on Cardiac Troponin I Concentration at
3 Months
Placebo
(n ¼ 314)
Fluticasone
Furoate 100
(n ¼ 311)
Vilanterol 25
(n ¼ 319)
Fluticasone
Furoate/Vilanterol
100/25 (n ¼ 314)
Baseline troponin, ng/l* 4.4 4.2 4.2 4.0
3-Month troponin, ng/l* 4.4 4.3 4.1 4.2
Adjusted ratio to baseline†
(95% CI)
1.02
(0.96–1.08)
1.02
(0.96–1.08)
0.98
(0.93–1.04)
1.02
(0.97–1.09)
Ratio of 3-month cardiac
troponin I in active
treatment vs. placebo
(95% CI)
1.00
(0.92–1.09)
0.96
(0.89–1.05)
1.01
(0.92–1.09)
p Value 0.947 0.404 0.893
Model is analysis of covariance of log transformed cardiac troponin I, adjusted for baseline cardiac troponin I, age,
sex, previous myocardial infarction, and previous hypertension. *Geometric mean. †The geometric means
displayed are unadjusted, whereas the ratio is based on the model.
CI ¼ conﬁdence interval.
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tionship between treatment-related changes in
plasma troponin concentration and modiﬁcation of
clinical risk.
Chronic obstructive pulmonary disease is an
important risk factor for the onset of CV disease.
Although there is a clear correlation between both
these conditions and established predisposing factors
such as age and smoking history, it appears that the
chronic inﬂammatory milieu that exists in patients
with COPD provides additional proatherosclerotic
impetus (31). A number of studies have begun to
explore this association (32,33), but questions have
persisted regarding the CV safety of inhaled therapies
for patients with COPD at increased CV risk (3,34).
The SUMMIT investigators addressed this uncertainty
with a large prospective superiority trial using the
primary endpoint of all-cause mortality. Notwith-
standing its nature as the largest ever randomized
placebo controlled trial in the treatment of COPD, the
12% relative reduction in risk was not statistically
signiﬁcant. This major endeavor could perhaps have
been avoided had a suitably speciﬁc and broadly
accepted surrogate indicator of treatment efﬁcacy
been available. Candidate biomarkers for the assess-
ment of both pulmonary and CV risk are plentiful;
however, most are nonspeciﬁc in nature and very few
have been demonstrated to hold promise in quanti-
fying treatment efﬁcacy (35). By contrast, cardiac
troponin arises solely from the myocardium (36), has
consistently demonstrated a strong association with
CV outcomes (5), is modiﬁable with medications (37),
and has shown robust correlation between treatment-
related concentration change and clinical events
(12,38). When considered alongside this evidence,our ﬁndings provide additional support for the
hypothesis that plasma cardiac troponin offers a role
in the assessment of novel CV interventions and
therapies.
Within this study, the troponin concentration that
determined the upper quintile was 7.7 ng/l. Compared
with the lowest quintile (<2.3 ng/l), the upper quin-
tile was associated with a greater than 3-fold
increased risk of all CV events and a 20-fold
increased risk of CV death. The application of a
troponin concentration threshold of $5 ng/l also
robustly dichotomized individuals into high- and
low-risk groups. This cutpoint of risk is remarkably
consistent with previous descriptions (11,12,21,39–41),
and supports the concept of a threshold value above
which event rates rise substantially. This threshold is
well below the 99th percentile upper reference limit
for this assay used for the diagnosis of myocardial
infarction, and adoption of troponin testing for CV
risk stratiﬁcation will require additional guidance for
clinicians. It is important to note that the distribution
of cardiac troponin is highly skewed in reference
populations (19), with the upper reference limit
increased markedly by a small number of outliers who
are likely to have subclinical disease. As such, the
cumulative evidence from studies evaluating prog-
nosis rather than diagnosis suggest that the threshold
to deﬁne low risk (the true normal, perhaps) is at
the much lower concentration of 5 ng/l (4). The
magnitude of increased risk we identiﬁed across
troponin quintiles is similar to that seen in both
primary and secondary CV disease prevention
populations, reinforcing its broad applicability for
prognostic stratiﬁcation (7,11,12). Importantly, this
threshold is above the 10% coefﬁcient of variation
for this assay, and could be used to guide treatment
decisions in clinical practice. Our ﬁndings have
implications for future research. Speciﬁcally, risk
stratiﬁcation with high-sensitivity cardiac troponin
could be used to more reliably identify and recruit
high-risk individuals into pharmacological interven-
tion trials, reducing required sample sizes and
avoiding the paradox whereby novel therapies are
studied in low-risk populations, but subsequently
prescribed for those at much greater risk.
STUDY LIMITATIONS. Our analyses are nonrandomized
comparisons, and there is a risk of bias if factors
correlated with both troponin and the outcome were
not included in our analysis. Due to the additional
requirement for specimen collection and storage at
baseline and 3 months, this substudy contained only
1,599 (10%) of the total number of participants
included in the primary SUMMIT analysis. The
FIGURE 2 High-Sensitivity Cardiac Troponin at Baseline or 3 Months and Risk of CV Composite Events, CV Death, and COPD Exacerbations
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Patients were grouped into those who had high-sensitivity cardiac troponin I concentrations <5 ng/l at both baseline and 3 months, and those with a concentration
$5 ng/l at either baseline or 3 months. Patients with cardiac troponin concentrations$5 ng/l at either time point had increased rates of the composite CV endpoint (A)
and CV death (B). By contrast, there was no difference in COPD exacerbations (C). Abbreviations as in Figure 1.
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broadly consistent with the full study analysis
although there were some differences in key charac-
teristics such as sex, body mass index, and use ofconcomitant therapies. In the absence of electrocar-
diography, we were unable to adjust for the presence
of arrhythmia, conduction defects, or left ventricular
hypertrophy. Despite employing a robust and precise
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with COPD, plasma concentrations of cardiac
troponin I are associated with future fatal and
nonfatal CV events but not with exacerbations of
COPD. Long-acting beta-agonists or ICS, alone or in
combination, do not reduce plasma troponin I
concentrations or CV events.
TRANSLATIONAL OUTLOOK: Serial measure-
ments of high-sensitivity cardiac troponin I could act
in future studies as a surrogate market of CV status in
patients with COPD and potentially assess the impact
of treatment before clinical events occur.
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1136assay, the average troponin concentrations were low
and similar to the concentration where total impre-
cision of the assay is 10%. This reinforces the need for
physicians and trialists to be aware of the analytical
characteristics of the locally available troponin assay
before implementing cardiac troponin monitoring in
clinical practice. Although analytical variation is
modest, even at low concentrations (42,43), when
considered at an individual patient level and in
combination with any biological variability in pa-
tients with COPD, these factors could result in
reclassiﬁcation of risk. Nevertheless, our ﬁndings are
concordant with previous studies evaluating the
prognostic role of high-sensitivity plasma cardiac
troponin testing using this assay (11,12,21,39,40).
Although future research studies are required to
quantify the effects of analytical and biological vari-
ability through repeated sampling in this patient
population, misclassiﬁcation could be addressed in
clinical practice through the use of serial troponin
measurements over consecutive clinic visits. This
would be analogous to the recommendation in clin-
ical guidelines to undertake repeated blood pressure
measurements on separate occasions before confer-
ring a diagnosis of hypertension.
CONCLUSIONS
In patients with combined respiratory and CV dis-
eases, high-sensitivity plasma cardiac troponin I
concentration is a prognostic marker that is speciﬁc toCV, but not respiratory, events. Plasma troponin I
concentrations were not modiﬁed by the inhaled
therapies for COPD investigated in this trial; a ﬁnding
concordant with the primary SUMMIT ﬁndings. As
such, high-sensitivity cardiac troponin I represents a
plausible surrogate indicator of the CV consequences
of novel medical therapies and interventions.
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